Science & Technology Review >

2015 , Vol. 33 >Issue 12: 77 - 82

DOI: https://doi.org/10.3981/j.issn.1000-7857.2015.12.013

Articles

Intervention of Edaravone on expression of β amyloid and amyloid precursor protein after cerebral ischemia reperfusion

  • REN Haiyan ,
  • ZHAO Hui ,
  • WANG Lei ,
  • XU Chenbo ,
  • MA Meilei ,
  • WEN Juan
Expand
  • 1. School of Basic Medicine, Xinjiang Medical University, Urumqi 830054, China;
    2. School of Traditional Chinese Medicine, Capital Medical University, Beijing 100054, China;
    3. Laboratory of Clinical Pharmacology, Nigata University of Pharmacy and Applied Life Sciences, Tokyo 956-8603, Japan

Received date: 2015-01-14

  Revised date: 2015-04-21

  Online published: 2015-07-15

Fold

Abstract

This paper investigates the damage mechanism of rat hippocampal neurons induced by the ischemia reperfusion and the intervention of the Edaravone. An ischemia reperfusion model is built by the middle cerebral artery occlusion (MACO)-reperfusion method. The reperfusion is performed 2 hours after the ischemia and persists for 22 hours (24 h since surgery). According to the Zea Longa's 5 level evaluation method, the neurobehavioral score of rats is graded; The rats' tissue pathological morphological changes are observed by the HE staining; the expressions of amyloid β (Aβ) and its precursor (APP) in the hippocampus of rats are detected with the immunohistochemistry, the image analysis and the Western Blot. It is shown that the model group rats show obvious symptoms of the nerve function defect; By contrast, the Edaravone of 6 and 10 mg/kg could improve model rats' symptoms of the nerve defect in varying degrees; And the difference is more significant in 10 mg/kg group (P<0.01). The HE staining shows that the depigmentation of the model group rat hippocampal neurons is obvious, and the two treatment groups could reduce this kind of morphology change; The immunohistochemistry and Western Blot analysis results suggest that both levels of Aβ and APP in the model group are significantly higher than those in the sham group (P<0.01), however, in different concentrations of Edaravone groups, their expression is significantly reduced (P<0.05). It is concluded that the ischemia reperfusion could cause neuron cells' damage by increasing Aβ and APP, and the Edaravone might suppress their toxic effects and protect the neuron cells by decreasing their expression.

Key words： cerebral ischemia reperfusion; &beta; amyloid; amyloid precursor protein; Edaravone; cerebral ischemia reperfusion; &beta; amyloid; amyloid precursor protein; Edaravone

Cite this article

REN Haiyan , ZHAO Hui , WANG Lei , XU Chenbo , MA Meilei , WEN Juan . Intervention of Edaravone on expression of β amyloid and amyloid precursor protein after cerebral ischemia reperfusion[J]. Science & Technology Review, 2015 , 33(12) : 77 -82 . DOI: 10.3981/j.issn.1000-7857.2015.12.013

References

[1] Manley G T, Binder D K, Papadopoulos M C, et al. New insights into water transport and edema in the central nervous system from phenotype analysis of aquaporin- 4 null mice[J]. Neuroscience, 2004, 129: 983-991.
[2] Hardy J A, Higgins G A. Alzheimer's disease: The amyloid cascade hypothesis[J]. Science, 1992, 25(6): 184-185.
[3] Jendroska K, Hoffmann O M, Patt S. Amyloid beta peptide and precursor protein (APP) in mild and severe brain ischemia[J]. Annals of the New York Academy of Sciences, 1997, 826: 401-405.
[4] Kalaria R N. The role of cerebral ischemia in Alzheimer's disease[J]. Neurobiol Aging, 2000, 21(2): 321-330.
[5] 闫福玲. 重视Alzheimer病与脑缺血的共病研究[J]. 国际脑血管病杂 志, 2006, 14(11): 801-802. Yan Fuling. Attaching importance to comorbidity study of Alzheimer's disease and cerebral ischemia[J]. International Journal of Cerebrovascular Diseases, 2006, 14(11): 801-802.
[6] Hardy J, Selkoe D J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics[J]. Science, 2002, 297(5580): 353-356.
[7] Woltjer R L, McMahan W, Milatovic D, et al. Effects of chemical chaperones on oxidative stress and detergent-insoluble species formation following conditional expression of amyloid precursor protein carboxyterminal fragment[J]. Neurobiology of Disease, 2007, 25(2): 427-437.
[8] Tillement L, Lecanu L, Papadopoulos V. Alzheimer's disease: Effects of beta-amyloid on mitochondria[J]. Mitochondrion, 2011, 11(1): 13-21.
[9] Cardoso S M, Proenca M T, Santos S, et al. Cytochrome c oxidase is decreased in Alzheimer's disease platelets[J]. Neurobiology of Aging, 2004, 25(1): 105-110.
[10] Gibson G E, Blass J P, Beal M F, et al. The alphaketoglutaratedehydrogenase complex: A mediator between mitochondria and oxidative stress in neurodegeneration[J]. Molecular Neurobiology, 2005, 31(1-3): 43-63.
[11] Pickrell A M, Fukui H, Moraes C T. The role of cytochrome c oxidase deficiency in ROS and amyloid plaque formation[J]. Journal of Bioenergetics and Biomembranes, 2009, 41(5): 453-456.
[12] Tauskela J S. MitoQ-a mitochondria-targeted antioxidant[J]. IDrugs, 2007, 10(6): 399-412.
[13] Spindler M, Beal M F, Henchcliffe C. Coenzyme Q10 effects in neurodegenerative disease[J]. Neuropsychiatric Disease and Treatment, 2009, 5: 597-610.
[14] Shen Y E, Wang Y, Yu G C, et al. Effects of edaravone on amyloid-β precursor protein processing in SY5Y- APP695 cells[J]. Neurotoxicity Research, 2013, 24: 139-147.
[15] Taupin P. A dual activity of ROS and oxidative stress on adult neurogenesis and Alzheimer's disease[J]. Central Nervous System Agents in Medicinal Chemistry, 2010, 10(1): 16-21.
[16] Green A R, Shuaib A. Therapeutic strategies for the treatment of stroke [J]. Drug Discovery Today, 2006, 11: 681-693.
[17] van der Worp H B, Kappelle L J, Algra A, et al. The effect of tirilazad mesylate on infarct volume of patients with acute ischemic stroke[J]. Neurology, 2002, 58: 133-135.
[18] Cuzzocrea S, Costantino G, Gitto E, et al. Protective effects of melatonin in ischemic brain injury[J]. Journal of Pineal Research, 2000, 29: 217-227.
[19] 王海征, 张秋霞, 赵晖, 等. 风药、补虚药对脑缺血大鼠淀粉样β蛋白 及其蛋白前体表达的影响[J]. 世界中医药, 2013, 8(8): 942-945. Wang Haizheng, Zhang Qiuxia, Zhao Hui, et al. Influence of winddispelling medicine assisted with deficiency-nourishing medicine on the expression of APP and Aβ42 for cerebral ischemic in rats model [J]. World Chinese Medicine, 2013, 8(8): 942-945.
[20] 李泰东, 陆国辉, 崔云燕, 等. 缺血再灌注对大鼠海马神经元淀粉样 蛋白及其蛋白前体表达的影响及人参皂甙Rg2的干预[J]. 中风与神 经疾病杂志, 2008(4): 417-420. Li Taidong, Lu Guohui, Cui Yunyan, et al. Effects of ischemia reperfusion on expression of amyloid and amyloid precursor protein in rat hippocampal neurons and the intervention of ginsenoside Rg2[J]. Journal of Apoplexy and Nervous Diseases, 2008(4): 417-420.
[21] Longa E Z, Weinstein P R, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in Rats[J]. Stroke, 1989, 20(1): 84-91.
[22] 韩晶, 冯加纯. 脑缺血损伤后β淀粉样蛋白及其前体蛋白在脑组织中 的表达及治疗[J]. 实用心脑肺血管病杂志, 2006, 14(12): 935-937. Han Jing, Feng Jiachun. Expression and treatment of β amyloid and its precursor protein in the brain after cerebral ischemia reperfusion injury[J]. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease, 2006, 14(12): 935-937.
[23] Selkoe D J. Alzheimer's disease: Genes, proteins, and therapy[J]. Physiological Reviews, 2001, 81(2): 741-766.
[24] Reiss A B. Cholesterol and apolipoprotein E in Alzheimer's disease[J]. American Journal of Alzheimer's Disease & Other Dementias, 2005, 20(2): 91-96.
[25] 苏心, 张文治, 吴剑娟. β淀粉样蛋白对培养胎鼠大脑神经干细胞作 用的研究[J]. 中华老年心脑血管病杂志, 2005, 7(3): 192-194. Su Xin, Zhang Wenzhi, Wu Jianjuan. Effect of amyloid-β protein on cultured neural stem cells of fetal rat[J]. Chinese Journal of Geriatric Heart Brain and Vessel Diseases, 2005, 7(3): 192-194.
[26] Nelson T J, Alkon D L. Oxidation of cholesterol by amyloid precursor protein and β- amyloid peptide[J]. Journal of Biological Chemistry, 2005, 280(8): 7377-7387.
[27] Hashimoto M, Rockenstein E, Crews L, et al. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's disease[J]. Neuromolecular Medicine, 2003, 4(1-2): 21-36.
[28] Renolleau S, Aggoun Z D, Ben A Y, et al. A model of transient unilateral focal ischemia with reperfusion in the P7 neonatal rat: Morphological changes indicative of apoptosis[J]. Stroke, 1998, 29(7): 1454-1461.
[29] Gervais F G, Xu D, Robert son G S, et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid- beta precursor protein and amyloidogenic A beta peptide formation[J]. Cell, 1999, 97(4): 395-406.
[30] Lee P H, Hwang E M. Effect of ischemic neuronal insults on amyloid precursor protein processing[J]. Neurochemitry Research, 2006, 31: 821-827.
[31] Perluigi M, Joshi G, Sultana R. In vivo protection by the xanthate tricyclodecan-9-yl-xanthogenate against amyloid beta-peptide(1-42)- induced oxidative stress[J]. Neuroscience, 2006, 138(4): 1161-1170.
[32] Watanabe T, Tahara M, Todo S. The novel antioxidant edaravone: From bench to bedside[J]. Cardiovascular Therapeutics, 2008, 26: 101-114.
[33] Yoshida H, Yanai H, Namiki Y, et al. Neuroprotective effects of edaravone: A novel free radical scavenger in cerebrovascular injury[J]. CNS Drug Reviews, 2006, 12: 9-20.
[34] Takamatsu Y, Yuki S, Watanabe T. Studies on the concentration of 3- methyl-1-phenyl-2-pyrazolin-5-one(MCI-186) in MCA occlusion and reperfusion model of rats[J]. Japan Pharmacology Therapeutics, 1997, 25(Supp l): S1785-S1791.
[35] Yang J, Cui X, Li J, et al. Edaravone for acute stroke: Meta-analyses of data from randomized controlled trials[J]. Developmental Neurorehabilitation, 2013, doi: 10.3109/17518423.2013.830153.
[36] Xiao B, Bi F F, Hu Y Q. Edaravone neuroprotection effected by suppressing the gene expression of the Fas signal pathway following transient focal ischemia in rats[J]. Neurotoxicity Research, 2007, 12 (3): 155-162.
Options
Outlines

/

〈 〉

Contact

  • Add：No. 86 Xueyuan South Road, Haidian District, Beijing　 Postal Code：100081
  • Tel: +86-10-62138113　Fax: +86-10-62138113
  • E-mail：kjdbbjb@cast.org.cn

    • Visited

      Total visitors:
      Visitors of today:
      Now online:
    Copyright © Science & Technology Review, All Rights Reserved.